Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Northern Biologics Inc., a UHN spin-off and developer of antibody-based therapeutics, was acquired Thursday by
Boehringer Ingelheim (BI), the world's largest private pharmaceutical company.
Northern Biologics was the first modern UHN spin-off backed by venture capital. Its acquisition follows in the footsteps of a string of similar successes for UHN spin-offs created by UHN's Technology Development and Commercialization office, including
Northern Biologics was founded in 2014 through the biggest biotech deal in Canada at the time. It was created based on licenses for intellectual property developed by Princess Margaret Cancer Centre Senior Scientists Drs. Benjamin Neel (currently at the Perlmutter Cancer Center), Brad Wouters and Robert Rottapel, and University of Toronto researchers Drs. Sachdev Sidhu and Jason Moffat.
Northern Biologics has pursued the development of new drugs and a platform for antibody generation. These efforts are advancing antibody-based treatments for cancer and fibrosis, with a focus on the emerging field of the tumor microenvironment – an important area of focus at UHN.
As with Bluerock Therapeutics, Northern Biologics operations have been located at the Princess Margaret Cancer Research Tower in the MaRS Discovery District since its founding. This enables close collaboration between the company and UHN's research community. Through this work, Northern Biologics has discovered and developed two programs acquired by Boehringer Ingelheim, and these assets are now progressing toward human clinical trials at UHN hospital sites, which will benefit local patients first.
Both BlueRock and Northern Biologics were founded through record-setting investments by global venture capital firm Versant Ventures. The success of these investments confirm the tremendous value of collaboration between industry and UHN researchers.
For more information,
read the press release.